Charles Schwab Investment Management Inc. Acquires 64,700 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Charles Schwab Investment Management Inc. lifted its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 14.6% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 507,448 shares of the company's stock after buying an additional 64,700 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.50% of Day One Biopharmaceuticals worth $7,069,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Intech Investment Management LLC purchased a new position in shares of Day One Biopharmaceuticals in the third quarter worth $324,000. First Turn Management LLC bought a new stake in Day One Biopharmaceuticals in the 3rd quarter valued at $13,204,000. Quest Partners LLC lifted its stake in Day One Biopharmaceuticals by 9,238.6% in the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company's stock worth $108,000 after purchasing an additional 7,668 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Day One Biopharmaceuticals in the 3rd quarter worth $825,000. Finally, TimesSquare Capital Management LLC boosted its holdings in shares of Day One Biopharmaceuticals by 8.2% during the 3rd quarter. TimesSquare Capital Management LLC now owns 1,827,695 shares of the company's stock valued at $25,460,000 after purchasing an additional 139,160 shares during the last quarter. Institutional investors own 87.95% of the company's stock.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN traded down $0.35 during trading on Thursday, hitting $12.81. The company had a trading volume of 972,519 shares, compared to its average volume of 959,083. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -12.44 and a beta of -1.51. The company has a fifty day simple moving average of $14.21 and a two-hundred day simple moving average of $14.04. Day One Biopharmaceuticals, Inc. has a one year low of $11.94 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.58. The company had revenue of $93.76 million during the quarter, compared to the consensus estimate of $15.05 million. During the same quarter in the prior year, the business earned ($0.54) earnings per share. On average, equities research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total value of $399,300.00. Following the sale, the insider now directly owns 1,034,015 shares in the company, valued at approximately $13,762,739.65. This represents a 2.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders sold 51,745 shares of company stock valued at $748,567. Company insiders own 8.40% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on DAWN shares. TD Cowen raised Day One Biopharmaceuticals to a "strong-buy" rating in a report on Monday, November 4th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Finally, Needham & Company LLC reiterated a "buy" rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $35.71.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.